Related Experiment Video
Updated: Aug 22, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention
Mehmet Akbulut1, Yilmaz Ozbay, Ilgin Karaca
1Firat University Faculty of Medicine, Department of Cardiology, Elazig, Turkey. drakbulut@hotmail.com
Insights
Long-term clopidogrel therapy significantly reduced neointimal formation and restenosis after coronary stent implantation. This antiplatelet treatment improved outcomes in patients without high-risk inflammatory responses post-procedure.
Area of Science:
- Cardiology
- Pharmacology
- Interventional Cardiology
Background:
- Neointimal formation after coronary stent implantation is a significant factor in restenosis.
- Antiplatelet therapy plays a crucial role in managing patients undergoing percutaneous coronary intervention (PCI).
- Understanding the long-term effects of specific antiplatelet agents like clopidogrel is essential for optimizing patient outcomes.
Purpose of the Study:
- To evaluate the long-term impact of clopidogrel-based antiplatelet therapy on neointimal hyperplasia following coronary stent implantation.
- To compare neointimal formation and restenosis rates between patients receiving continued clopidogrel and those switched to placebo.
Main Methods:
- A study involving 78 patients with stable angina or myocardial ischemia who underwent successful single-vessel stenting.
- Patients received dual antiplatelet therapy (clopidogrel and aspirin) for four weeks, after which half were switched to placebo for 20 weeks.
- Coronary angiography and intravascular ultrasound were performed at 24 weeks to assess in-stent neointimal formation and restenosis rates.
Main Results:
- The clopidogrel group exhibited significantly smaller angiographic stenosis diameter and lower restenosis rates compared to the placebo group (23.3% vs. 35.6% and 5.12% vs. 10.25%, respectively).
- Intravascular ultrasonography revealed a significantly smaller neointimal cross-sectional area in the clopidogrel group (3.6 mm² vs. 5.2 mm²).
Conclusions:
- Long-term administration of clopidogrel effectively reduces neointimal formation at the stent site.
- Clopidogrel therapy also contributes to reducing major clinical events in patients who do not exhibit a high-risk systemic inflammatory response post-PCI.
Objective:
The purpose of this study was to evaluate the long term effect of clopidogrel-based antiplatelet therapy on neointimal formation.
Methods:
This study comprised 78 patients with typical stable angina pectoris or documented myocardial ischaemia, and with only one angiographic lesion in one native coronary artery undergoing successful stent implantation without predilatation with C-reactive protein levels < or =5 mg/l at 72 h after the procedure. All patients received dual antiplatelet therapy with 75 mg/day clopidogrel and 300 mg/day aspirin for four weeks. Clopidogrel was switched to isochronous placebo in half of the patients (n=39) at the end of the fourth week. This allocation was maintained for 20 weeks, and at week 24 of the study, coronary angiography and intravascular ultrasound imaging were performed again in all cases in order to evaluate the changes that had occurred in the in-stent neointimal formation; rates of restenosis were also recorded
Results:
At the end of the follow-up period, angiographic stenosis diameter and restenosis rates were smaller in the clopidogrel group than in the placebo group (23.3% versus 35.6%, p=0.05 and 5.12% versus 10.25%; p=0.03 respectively); the intravascular ultrasonographic neointimal cross sectional area was also smaller in the clopidogrel group (3.6 +/- 2.7 mm(2) versus 5.2 +/- 2.5 mm(2), p=0.03).
Conclusions:
Long-term clopidogrel administration significantly reduced neointimal formation at the stent site as well as reducing major clinical events in patients who did not develop high-risk systemic inflammatory response after percutaneous coronary intervention.
